Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Zymeworks BC Inc (NASDAQ: ZYME) closed at $13.06 down -0.61% from its previous closing price of $13.14. In other words, the price has decreased by -$0.61 from its previous closing price. On the day, 0.52 million shares were traded. ZYME stock price reached its highest trading level at $13.335 during the session, while it also had its lowest trading level at $12.8.
Ratios:
For a deeper understanding of Zymeworks BC Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.10 and its Current Ratio is at 4.10. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on November 07, 2024, Upgraded its rating to Outperform and sets its target price to $25 from $10 previously.
On November 01, 2024, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight but kept the price unchanged to $12.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 05 ’24 when Galbraith Kenneth sold 18,198 shares for $10.65 per share. The transaction valued at 193,849 led to the insider holds 29,468 shares of the business.
Galbraith Kenneth sold 5,706 shares of ZYME for $63,996 on Jan 08 ’24. The Chair & CEO now owns 23,762 shares after completing the transaction at $11.22 per share. On Jan 05 ’24, another insider, Astle Christopher, who serves as the SVP & Chief Financial Officer of the company, sold 4,563 shares for $10.65 each. As a result, the insider received 48,606 and left with 7,934 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 905050176 and an Enterprise Value of 622618496. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.58 while its Price-to-Book (P/B) ratio in mrq is 2.50. Its current Enterprise Value per Revenue stands at 10.01 whereas that against EBITDA is -5.428.
Stock Price History:
Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $7.97. The 50-Day Moving Average of the stock is -7.04%, while the 200-Day Moving Average is calculated to be 17.75%.
Shares Statistics:
For the past three months, ZYME has traded an average of 545.80K shares per day and 378000 over the past ten days. A total of 69.58M shares are outstanding, with a floating share count of 67.09M. Insiders hold about 3.39% of the company’s shares, while institutions hold 97.32% stake in the company. Shares short for ZYME as of 1732838400 were 4632532 with a Short Ratio of 7.71, compared to 1730332800 on 4700126. Therefore, it implies a Short% of Shares Outstanding of 4632532 and a Short% of Float of 8.290000000000001.
